PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14658569

Recent developments in cervical cancer control.

Daniel F I Kurtycz·John E Shalkham
View original source ↗Export metadata ↓

Abstract

The Wisconsin State Laboratory of Hygiene's Cytology Program has contributed to the success of the Pap smear in substantially decreasing the number of cervical cancers in the United States. In addition to providing testing services to the Cervical Cancer Control Program of Wisconsin, the Department of Health and Family Services, and Planned Parenthood of Wisconsin, the Wisconsin State Laboratory of Hygiene (WSLH) maintains one of the largest schools of cytotechnology in the United States, which helps train individuals into a profession experiencing severe shortages. The Cytology Program has actively evaluated the new liquid-based testing technology to provide data to improve laboratory performance. Staff at the WSLH have participated in the evolution of cytopathology by serving on governmental committees and on professional cytopathology organizations. The WSLH Cytology Program is now evaluating the role of molecular technology, including human papilloma virus testing, to improve the diagnosis and treatment of cervical cancers.

Explore related subjects

Cell BiologyFemaleHumansLaboratoriesMass ScreeningPublic Health AdministrationQuality ControlState GovernmentUterine Cervical NeoplasmsWisconsinJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Daniel F I Kurtycz, John E Shalkham. 2003. Recent developments in cervical cancer control.. https://pubmed.ncbi.nlm.nih.gov/14658569/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic ductal adenocarcinoma.

MYC amplification contributes to poor survival and outcome in pancreatic ductal adenocarcinoma (PDAC). Here we show that in PDAC cell lines with amplified MYC, MondoA is required for viability, facilitating proliferation while suppressing apoptosis in vitro and in vivo. Transcriptional and genomic profiling demonstrates that loss of MondoA leads to altered expression of direct MondoA targets as well as MYC target genes and is accompanied by shifts in genomic occupancy of MYC, MNT, and the MondoA paralog ChREBP. This altered genomic binding by MYC network members is associated with transcriptional perturbation of multiple metabolic and stress pathways, as well as global changes in N6-methyladenosine modification (m6A) of mRNA. MondoA inhibition disrupts coordination between MYC network members and the Integrated Stress Response (ISR), resulting in decreased translation of ATF4 mRNA, discordant gene regulation of shared targets of MYC and ATF4 and, ultimately, apoptosis. Re-establishing ATF4 protein expression rescues the diminished viability due to loss of MondoA expression or activity, providing direct evidence of a link between deregulated MYC and the transcriptional machinery of the ISR. Lastly, we find that small-molecule inhibition of MondoA is lethal in a subset of PDAC cell lines, including patient-derived organoids, suggesting that the ability to target MYC via chemical inhibition of MondoA transcriptional activity may have broad efficacy.

Cell Biology↗